Cumulative Equivalence: Controlling for Inter-Individual Differences at Baseline Characteristic Testing of RCTs
John Damiao
Global Journal of Health Science, 2022, vol. 14, issue 7, 32
Abstract:
Randomized control trials (RCTs) are regarded as the gold standard for intervention research. The randomization process is intended to establish comparability between groups, so that the study outcomes can be attributable to the intervention, rather than group differences. The purpose of this paper is to emphasize the inherent risks of conducting multiple tests in the establishment of equivalency at baseline while omitting the cumulative effect of small group differences in RCTs. Randomization does not thoroughly prevent differences in group averages at the specific characteristic level. Any baseline differences that benefit the intervention group when accumulated over multiple categories of demographic characteristics described herein as cumulative inequivalence can significantly impact the internal validity of RCTs. This paper describes a procedure for assessing for cumulative inequivalence, as well as procedures such as re-randomization prior to intervention to establish comparability and thus promote cumulative equivalence of RCTs.
Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:
Downloads: (external link)
https://ccsenet.org/journal/index.php/gjhs/article/download/0/0/47365/50760 (application/pdf)
https://ccsenet.org/journal/index.php/gjhs/article/view/0/47365 (text/html)
Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:ibn:gjhsjl:v:14:y:2022:i:7:p:32
Access Statistics for this article
More articles in Global Journal of Health Science from Canadian Center of Science and Education Contact information at EDIRC.
Bibliographic data for series maintained by Canadian Center of Science and Education ().